검색어 : 통합검색[Raymond Fred]
총 737건 중 737건 출력
, 72/74 페이지
-
711
- Detection of Copy Number Alterations in DNA Repair/Repair-Related Genes for a Diversity of Hematologic Malignancies Identifies Disease-Specific Biomarkers of Potential Clinical Relevance.
- Schultz, Roger A; Brown, Theresa C.; Campbell, Lynda J; Wall, Meaghan; Schoumans, Jacqueline; Han, Jin-Yeong; Surti, Urvashi; Stewart, S. Dwanna; Fang, Min; Fink, James M; Tubbs, Raymond R.; Cook, James R.; Gitelson, Elena; McDaniel, Lisa D; Shaffer, Lisa G; Ballif, Blake C; Signature Genomic Laboratories, PerkinElmer Inc., Spokane, WA, USA,; Cytogenetics, CSI Laboratories, Alpharetta, GA, USA,; Victorian Cancer Cytogenetics Service, St. Vincent's Hospital Melbourne, Fitzroy, Australia,; Victorian Cancer Cytogenetics Service, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia,; Cancer Cytogenetic Unit, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland,; Department of Laboratory Medicine and Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine, Busan, South Korea,; University of Pittsburgh, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA,; Cytogenetics, Genetics Associates Inc., Nashville, TN,; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA,; Clinical Cytogenetics and Hematopathology, Hennepin County Medical Center, Minneapolis, MN, USA,; Department of Molecular Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA,; Patholog; (Blood, v.120, 2012, pp.2531-2531)
-
712
- Low Incidence of Complete Remission but Comparable Event-Free Survival(EFS) and Overall Survival (OS) with a History of Prior Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Myeloma (SMM) among Patients Receiving Total Therapy 2 (TT 2).
- Fassas, Athanasios; Barlogie, Bart; Rasmussen, Erik; Milner, Teresa; Terry, Julian; Zangari, Maurizio; Talamo, Giampaolo; Lee, Choon-Kee; Thertulien, Raymond; Crowley, John; Tricot, Guido; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Cancer Research And Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Cancer Research And Biostatistics,; (Blood, v.104, 2004, pp.932-932)
-
713
- Disentangling the lifespans of hepatitis C virus‐infected cells and intracellular vRNA replication‐complexes during direct‐acting anti‐viral therapy
- Cardozo, Erwing Fabian; Ji, Dong; Lau, George; Schinazi, Raymond F.; Chen, Guo‐ feng; Ribeiro, Ruy M.; Perelson, Alan S.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; The Fifth Medical Center of Chinese, PLA General Hospital (302 Hospital)‐ Hong Kong Humanity and Health Hepatitis C Diagnosis and Treatment Centre, Beijing, China; The Fifth Medical Center of Chinese, PLA General Hospital (302 Hospital)‐ Hong Kong Humanity and Health Hepatitis C Diagnosis and Treatment Centre, Beijing, China; Department of Pediatrics, Center for AIDS Research, Emory University School of Medicine, Atlanta, GA, USA; The Fifth Medical Center of Chinese, PLA General Hospital (302 Hospital)‐ Hong Kong Humanity and Health Hepatitis C Diagnosis and Treatment Centre, Beijing, China; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N; (Journal of viral hepatitis, v.27, 2020, pp.261-269)
-
714
- Histone Deacetylase Inhibition Elicits an Evolutionarily Conserved Self-Renewal Program in Embryonic Stem Cells
- Ware, Carol B.; Wang, Linlin; Mecham, Brigham H.; Shen, Lanlan; Nelson, Angelique M.; Bar, Merav; Lamba, Deepak A.; Dauphin, Derek S.; Buckingham, Brian; Askari, Bardia; Lim, Raymond; Tewari, Muneesh; Gartler, Stanley M.; Issa, Jean-Pierre; Pavlidis, Paul; Duan, Zhijun; Blau, C. Anthony; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA; MD Anderson Cancer Center, Houston, TX 77030, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98195, USA; Department of Medicine/Hematology, University of Washington, Seattle, WA 98195, USA; Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA; Department of Pathology, University of Washington, Seattle, WA 98195, USA; Department of Psychiatry and Centre for High-Throughput Biology, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; Institute for S; (Cell stem cell, v.4, 2009, pp.359-369)
-
715
- Fanconi anemia‐isogenic head and neck cancer cell line pairs: A basic and translational science resource
- Nguyen, Hiep Tai; Tang, Weiliang; Webster, Andrew L. H.; Whiteaker, Jeffrey R.; Chandler, Christopher M.; Errazquin, Ricardo; Roohollahi, Khashayar; Fritzke, Madeline; Hoskins, Elizabeth E.; Jonlin, Erica; Wakefield, Leslie; Sullivan, Lucas B.; Chen, Eleanor Y.; Dorsman, Josephine; Brakenhoff, Ruud; Paulovich, Amanda G.; Grompe, Markus; Garcia‐ Escudero, Ramon; Wells, Susanne I.; Smogorzewska, Agata; Monnat Jr, Raymond J.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA; Laboratory of Genome Maintenance, Rockefeller University, New York, New York, USA; Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, Washington, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA; Instituto de Investigació n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain; Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington; (International journal of cancer: Journal international du cancer, v.153, 2023, pp.183-196)
-
716
- Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
- Gertz, Morie A.; Cohen, Adam D.; Comenzo, Raymond L.; Kastritis, Efstathios; Landau, Heather J.; Libby, Edward N.; Liedtke, Michaela; Sanchorawala, Vaishali; Schö nland, Stefan; Wechalekar, Ashutosh; Zonder, Jeffrey A.; Palladini, Giovanni; Walling, Jackie; Guthrie, Spencer; Nie, Christie; Karp, Carol; Jin, Yuying; Kinney, Gene G.; Merlini, Giampaolo; 1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN; 2Abramson Cancer Center, The Hospital of the University of Pennsylvania, Philadelphia, PA; 3Divison of Hematology and Oncology, Tufts Medical Center, Boston, MA; 4Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 5Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY; 6Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA; 8Stanford Cancer Institute, Stanford, CA; 9Amyloidosis Center, Boston University School of Medicine, Boston, MA; 10Medical Department V, Amyloidosis Center, Universitä tsklinikum Heidelberg, Heidelberg, Germany; 11Division of Medicine, National Amyloidosis Centre, University College of London, Royal Free Hospital, London, United Kingdom; 12Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI; 13; (Blood, v.142, 2023, pp.1208-1218)
-
717
- Nonnegligible Increasing Temporal Trends in Unprotected Anal Intercourse Among Men Who Have Sexual Relations With Other Men in Montreal
- George, Clemon; Alary, Michel; Otis, Joanne; Demers, Eric; Remis, Robert S.; Mâ sse, Benoî t; Lavoie, René ; Vincelette, Jean; Parent, Raymond; LeClerc, Roger; Turmel, Bruno; Mental Health Services, St. Michael's Hospital, Toronto, Ontario, Canada; Unité de recherche en santé des populations, Centre Hospitalier Affilié Universitaire de Qué bec and Université Laval, Qué bec, Qué bec, Canada; Dé partement de Sexologie, Université du Qué bec à Montré al, Montré al, Qué bec, Canada; Unité de recherche en santé des populations, Centre Hospitalier Affilié Universitaire de Qué bec and Université Laval, Qué bec, Qué bec, Canada; Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchison Research Center, Seattle, WA; COCQ-Sida, Montré al, Qué bec, Canada; Service de Microbiologie, Centre Hospitalier de l'Université de Montré al, Hô pital Saint-Luc, Montré al, Qué bec, Canada; Institut; (Journal of acquired immune deficiency syndromes : JAIDS, v.42, 2006, pp.207-212)
-
718
- Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T.
- Thertulien, Raymond; Barlogie, Bart; Zangari, Maurizio; Fassas, Athanasios; Stover, Julie; Milner, Teresa; Rasmussen, Erik; Anaissie, Elias; Lee, Choon-Kee; Hollmig, Klaus; Talamo, Giampaolo; Tricot, Guido; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Cancer Research And Biostatistics, Fred Hutchinson Cancer Center, Seattle, WA, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Myeloma Institute for Research & Th; (Blood, v.104, 2004, pp.934-934)
-
719
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman’s Disease
- Wong, Raymond S; Casper, Corey; Munshi, Nikhil; Ke, Xiaoyan; Fosså , Alexander; Simpson, David; Capra, Marcelo; Liu, Ting; Hsieh, Ruey Kuen; Goh, Yeow Tee; Zhu, Jun; Cho, Seok-Goo; Ren, Hanyun; Cavet, James; Bandekar, Rajesh; Rothman, Margaret; Puchalski, Thomas A; Chaturvedi, Shalini; van de Velde, Helgi; Vermeulen, Jessica; van Rhee, Frits; Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong,; Fred Hutchinson Cancer Research Center, Seattle, WA, USA,; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,; Peking University Third Hospital, Beijing, China,; The Norwegian Radium Hospital, Oslo, Norway,; North Shore Hospital, Takapuna Auckland, Auckland, New Zealand,; Hospital Mã e de Deus, Porto Alegre, Brazil,; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China,; Mackay Memorial Hospital, Taipei, Taiwan,; Singapore General Hospital, Singapore, Singapore,; Beijing Cancer Hospital, Beijing, China,; Seoul St. Mary's Hospital, Seoul, South Korea,; Peking University First Hospital, Beijing, China,; The Christie NHS Foundation Trust/University of Manchester, Manchester, United Kingdom,; Janssen Research & Development, Spring House, PA, USA,; Janssen Research & Development, Washington, GA, USA,; Janssen Research & Development, Spr; (Blood, v.122, 2013, pp.505-505)
-
720
- Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)
- Whitlock, James; dalla Pozza, Luciano; Goldberg, John M; Silverman, Lewis B.; Ziegler, David S.; Attarbaschi, Andishe; Brown, Patrick; Gardner, Rebecca A; Gaynon, Paul S.; Hutchinson, Raymond J.; Marcus, Leigh J.; Messinger, Yoav H.; Schultz, Kirk R.; Vandergiessen, Jeannette; Eckroth, Elena; Locatelli, Franco; Zwaan, C Michel; Wood, Brent L.; Sposto, Richard; Gore, Lia; The Hospital for Sick Children, Toronto, Canada; Children's Hospital at Westmead, Sydney, Australia; University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL; Dana-Farber Cancer Institute, Boston, MA; Sydney Children's Hospital, Sydney, Australia; St. Anna Children's Hospital, Vienna, Austria; Johns Hopkins University School of Medicine, Baltimore, MD; Seattle Children's Hospital, Seattle, WA; Childrens Hosp. of Los Angeles, Los Angeles, CA; University of Michigan, Ann Arbor, MI; Children's National Medical Center, Washington, DC; Children's Hospitals and Clinics, Saint Paul, MN; B.C. Children's Hospital, University of British Columbia, Vancouver, Canada; Children's Hospital Los Angeles, Los Angeles, CA; Children's Hospital Los Angeles, Los Angeles, CA; IRCCS Bambino Gesù Children's Hospital Rome, University of Pavia, Rome, Italy; Erasmus MC/Sophia Children's Hospital, Rotterdam, Netherlands; Fred Hutchinson Cancer Resea; (Blood, v.124, 2014, pp.795-795)
QUICK MENU
